Impact of alpha-lipoic acid on salivary production in patients receiving radiotherapy for head and neck cancer: a randomized clinical study - Scorecard - MDSpire
Advertisement
Impact of alpha-lipoic acid on salivary production in patients receiving radiotherapy for head and neck cancer: a randomized clinical study
Clinical Scorecard: Impact of alpha-lipoic acid on salivary production in patients receiving radiotherapy for head and neck cancer: a randomized clinical study
At a Glance
Category
Detail
Condition
Key Mechanisms
Alpha-lipoic acid (ALA) mitigates acinar cell destruction and enhances salivary secretion through its antioxidant properties, potentially restoring gland function.
Target Population
Care Setting
Key Highlights
Significant improvement in salivary output observed with ALA administration; specify percentage increase if available.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess salivary output and quality of life post-radiotherapy.
Monitor for potential adverse effects of ALA, including gastrointestinal disturbances and allergic reactions.
Risks
Patient & Prescribing Data
ALA (300 mg) administered daily for the duration of radiotherapy to evaluate its efficacy in preserving salivary function.
Clinical Best Practices
Incorporate antioxidant therapies like ALA in treatment plans for patients undergoing head and neck radiotherapy, supported by recent clinical findings.
April is Head and Neck Cancer Awareness Month, highlighting a diverse group of diseases that account for nearly 5% of all cancers in the United States.
